New report on CNS, metabolic, immunologic disorders, infection, cardiovascular disease and oncology therapeutic markets
July 08, 2017
- Key M&A activities and licensing agreements that have taken place between 2005 and 2010 in the global Oncology, CNS disorders, immunological disorders, infection, metabolic disorders and cardiovascular disorders markets
Reasons to buy
- Align your product portfolio to the markets with high growth potential
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety
- Develop key strategic initiatives by understanding the key focus areas of leading companies
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps
SOURCE Reportlinker